Duglimax (metformin hydrochloride) tablets 500 mg/2 mg. №60


Manufacturer: Germany

As a Supplement to diet and exercise for patients with insulin-dependent type II diabetes: if monotherapy with sulfonylureas or Metformin does not provide an appropriate level of glycemic control; when replacing combined therapy with sulfonylureas and Metformin.



Duglimax Composition:

active ingredients:
excipients (tablets 500 mg / 1 mg): sodium carboxymethyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, iron oxide red (E 172)
excipients (tablets 500 mg / 2 mg): sodium carboxymethyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, Pigment Blend PB-51323 green.

Duglimax Dosage form.


Duglimax Pharmacotherapeutic group.

Antidiabetic drugs. A combination of oral hypoglycemic drugs. ATC code А10В D02.

Clinical characteristics.


As an addition to diet and exercise for patients with non-insulin dependent diabetes mellitus type II:

if monotherapy with sulfonylureas or metformin does not provide an adequate level of glycemic control
when replacing combination therapy with sulfonylureas and metformin.


Insulin-dependent type I diabetes mellitus (for example, diabetes with a history of ketonemia), diabetic ketonemia, diabetic coma and precoma, acute or chronic metabolic acidosis.
Hypersensitivity to any of the excipients that make up this drug, sulfonylureas, sulfonamides or biguanides.
Severe liver dysfunction or stay on hemodialysis (so far there is no experience with the use of the drug). In the case of severe impairment of liver and kidney function, in order to achieve proper control of the patient’s blood sugar level, it is necessary to switch to insulin.
Severe infections, conditions before and after surgery, severe trauma.
Malnutrition, starvation or exhaustion of the patient, or also hypofunction of the pituitary gland or adrenal glands in the patient.
Liver dysfunction, severe pulmonary dysfunction and other conditions that are likely to be accompanied by hypoxemia, excessive alcohol consumption, dehydration, gastrointestinal disorders, including diarrhea and vomiting.
Congestive heart failure requiring medical treatment Recent myocardial infarction, severe circulatory problems, or shortness of breath.
Impaired renal function.

Method of administration and dosage.

The dose of antidiabetic drugs must be selected individually, taking into account the patient’s blood sugar level.
The starting dose of this drug is recommended to be prescribed in the form of the minimum effective dose in the following clinical situations.
For patients in whom diabetes is not controlled with monotherapy with sulfonamides or metformin, the usual starting dose of this drug is 500/1 mg mg, which is prescribed once a day and which can be adjusted depending on the concomitant therapy with another antidiabetic agent or according to the level of glycemia the patient. When transferring from sulfonylurea preparations with a long half-life (for example, from chlorpropamide), the patient should be carefully monitored, since hypoglycemia may occur as a result of the increased effect of the drugs. When transferring from combination therapy with individual tablet drugs: the usual starting dose is the dose of glimepiride and metformin that is already being taken.
If necessary, the dose can be increased to 3 tablets per day, the highest daily dose at the rate of 6 mg glimepiride per day, taking into account the therapy used, the effectiveness or tolerability of the drug. In this regard, it is necessary to carefully monitor blood sugar levels.
A daily dose of glimepiride in excess of 6 mg is more effective in only a small number of patients.
The drug should be taken 1 time per day before or during breakfast or the first main meal.
Errors in drug use, such as skipping a dose, should never be corrected by taking a higher dose later.
The tablet should be swallowed whole without breaking or chewing.